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Abstract 
 Over 4,000 flavonoids have been identified, and among these, many of them are 
known to possess cardioprotective, anti-inflammatory, antimicrobial, and antitumor 
effects.  However, most of these properties have yet to be fully understood.  In this study, 
extracts from Gnaphalium gracile, thought to possess a mixture of flavonoids, have been 
tested for cytotoxic activity on pancreatic (MiaPaca, Panc28), colon (HCT-116, Caco-2), 
and prostate (PC3, LNCaP), cancer cell lines.  Polar extracts from the leaves of G. gracile 
have the most cytotoxic effect on these cancer cell lines, particularly the prostate cancer 
cell lines PC3 and LNCaP.  Evidence suggests the extracts have antineoplastic effects on 
these cancer cells lines possibly due to differentiation status on pancreatic and colon 
cancer, but not prostate cancer.  Cytotoxic activity is not dependent on tumorigenic 
potential.  Further research is needed to identify the bioactive compounds within these 
extracts. 
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Introduction 
In 2014 alone, an estimated 376,250 people will be diagnosed with colon, 
pancreatic, or prostate cancer [1,2,3].  Characterized by the uncontrolled growth of cells 
of the respective organ sites, these cancers can be fatal if not diagnosed early.  The five-
year survival rates of these cancers, with the exception of prostate cancer, are extremely 
low.  For pancreatic cancer, the five-year survival rate is 1-14% depending on how far the 
cancer has progressed [4].  With survival rates of 6-74% [5], colon cancer survival rates 
are much more dependent on an early diagnosis.  Five-year survival rates of men with 
prostate cancer are nearly 100% due to the ability to remove the prostate [6], but it drops 
to 27.8% for metastatic disease [7]. Thus, there is a continued need   for newer treatment 
approaches in order to better control metastatic prostate cancer and improve survival.   
 Modern medicine has developed three main treatment options for combatting 
different types of cancer.  These options are available for healthcare providers to choose 
from:  surgery, radiation therapy, and chemotherapy.   
Perhaps the most effective means to treat cancer is physically removing the 
malignancy from the body [8].  Although surgery has the best chance of sending patients 
into remission, there are many detrimental effects to the patient physically and mentally.  
Frequently, large parts of the organ or the whole organ must be removed to excise all of 
the cancerous tissue.  This leaves the patient with a loss of function, which decreases 
quality of life in the short and long term. Additionally, it is often difficult to convince the 
patient to undergo surgery.  The idea of a major surgery is daunting for many patients 
who have never dealt with a similar situation.  As a result, families typically suffer 
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because they watch their loved ones slowly decline in health when there is a treatment 
option available.   
 Radiation therapy is defined as the treatment of cancer patients using high-energy 
particles or waves directed at the site of the malignancy.  Radiation works by damaging 
the DNA of cancer cells.  When the DNA is damaged, parent cells can no longer divide 
and are eliminated from the body, thus halting the growth of the tumor.  Although an 
effective means of destroying cancer cells, radiation therapy also destroys the DNA of 
normal cells in the body.  As a result, healthcare providers must plan radiation treatment 
so that damage to normal cells is minimized.  Because of this, there are many side effects 
of radiation treatment.  Normal actively dividing cells in the body such as those of the 
salivary gland or epithelial tissue are also especially vulnerable to this type of treatment.  
Many patients suffer from nausea and vomiting, hair loss, and overall fatigue from 
radiation therapy [9].   
 Chemotherapy is a widely used treatment option and is characterized by the use of 
drugs to combat cancer cells.  Chemotherapy targets cells that are actively growing and 
dividing.  However, some agents may also include cells that are not traversing the cell 
cycle. As mentioned earlier, normal cells of the body such as epithelial tissue are always 
actively growing and dividing, so they become vulnerable to chemotherapy as well.  
Chemotherapy is similar to radiation therapy in that the side effects of the treatment occur 
when normal cells are destroyed in the process of targeting the tumorigenic cells.  
However, the main difference between the other two main treatment options and 
chemotherapy is that it has the capacity to work throughout the body whereas surgery and 
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radiation therapy are limited to specific areas.  In this way, chemotherapy may in some 
cases be a more effective method of treating metastatic tumors [10]. 
 With these treatment options and statistics in mind, it is easy to see the need for 
more effective means of treating patients with varying stages of cancer that do not result 
in the physical and psychological damage that is typically seen in these individuals.  For 
example, according to Ashbury et. al., about 14% of cancer patients are prescribed anti-
depressants [11].  Clinically depressed patients experience a lower quality of life that may 
have been avoided if current treatment options were able to eliminate the physical and 
psychological damage that inevitably impact most cancer patients.   
To investigate other treatment options that spare normal cells, ethnobotanical 
studies were considered.  For the treatment of cancer, in the Andean regions of South 
America, there is a group of medicinal plants known as vira-viras.  They belong to the 
family Asteraceae and to the genera Gnaphalium, Achyrocline, and Gamochaeta.  They 
are annuals or perennials that grow between 2,000 and 3,000 meters above sea level.  In 
this region and other parts of the world, they are used as a hemostatic, to ease 
inflammation, and to fight infection.  In this region of South 
America, these plants are commonly used to battle cancer 
[12].  In this study, extracts from Gnaphalium gracile were 
tested for antineoplastic activity on cancer cells from the 
colon, pancreas, and prostate with varying states of 
differentiation.  Among the bioactive compounds present in 
these extracts, flavonoids stand out as the molecule with the highest therapeutic potential.  
Certain flavonoids have been shown to promote defense mechanisms against cancer, 
Gnaphalium gracile taken 
by R.  Torrenegra 
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partly due to the counteraction of free radicals in the body [13].  Other flavonoids and 
flavonoid derivatives [14] have been shown to induce cell cycle arrest, particularly at the 
G1/S [15] and G2/M [16] phases.  In other studies, certain flavonoids have been observed 
to stimulate DNA repair machinery [17].  In many instances, there is an inverse 
relationship with dietary flavonoid intake and risk of cancer [18].  The role of these 
compounds as a potential ingredient in therapeutic drugs has yet to be fully explored.   
Because of the known properties of flavonoids, it has been hypothesized that the extracts 
from Gnaphalium gracile will demonstrate significant antineoplastic activities against the 
cancer cell lines.    
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Materials and Methods 
Cell Culture  
Tumor derived cells that originated in multiple tissue sites were obtained from the 
American Tissue Type Culture Collection (ATCC, Manasas, VA), including colon 
(Caco-2 and HCT-116), pancreatic (MIA PaCa), and prostate (LNCaP and PC-3), and 
were maintained according to ATCC instructions.  These cell lines, including their 
differentiation status are highlighted in Table 1.  The Panc-28 cell line was a gift from 
Dr. Paul Chiao (University of Texas M. D. Anderson Cancer Center, Houston, TX) and 
was grown in tissue culture in the same manner as pancreatic cell line MIA PaCa-2, in 
Dulbecco’s modified Eagle’s medium with high glucose, supplemented with 10% serum 
and penicillin/streptomycin (GIBCO Invitrogen, Carlsbad, CA). All cells were seeded in 
48 well plates and allowed to reach 75% confluency before treatment.   
 
Cell Line Differentiation Status 
Pancreas - MiaPaca Poor 
Pancreas – Panc28 Better 
Colon – HCT - 116 Poor 
Colon - CaCo-2 Better 
Prostate – PC3 Poor 
Prostate - LNCaP Better 
 
Table 1:  Name and differentiation status of each cell line.  Poorly 
differentiated cells lines are less similar to their normal cell counterparts.  Better-
differentiated cell lines are more like normal cells.  Differentiation status is used 
to determine the grade of the cancer and assist in planning treatment options for 
patients.  
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Procedure to Obtain Extracts 
Plants of G. gracile HBK were collected during the months of July through 
September in the area surrounding the Tominé reservoir, in the municipality of Guatavita, 
in Cundinamarca, Colombia. The specimens were identified at the Colombian National 
Herbarium. Leaves and flowers were separated, dried in the shade, and soxhlet extracted 
with AcOEt. From 230g of flowers, 17g of extract was obtained. Following the same 
procedure, but separately, 70g of extract was obtained from 645g of leaves and stems. 5g 
of each extract were fractionated sequentially with petrol and ethanol, to obtain the apolar 
fractions (in petrol) and polar (in EtOH) of leaves and flowers. The fractions were 
designated as EF apolar, EF polar, and EH polar, EH apolar for flowers and leaves 
respectively, and were subsequently dried under vacuum. A 10g sample of leaf extract 
was subjected to column chromatography on SiGel, with mobile phase Petrol: EtOAc 8: 
2. Fractions of 50 mL were collected and isolated and identified as stigmasterol, 
dehidroestigmasterol and gnaphaline in fractions 6 and 12 respectively. In the same 
manner, gnaphalin A was identified after isolation from the flower extracts. It was found 
in a higher proportion of about 0.3% of dry material. Column chromatography with 
mobile phase RP18 and EtOH : water 7:3, using the polar extract of leaves or flowers, 
quercetine, and a mixture of 3- methoxyquercetine and quercetin were found. The 
compounds were identified by comparison of their spectra with 1HNMR and 13CNMR 
spectra of authentic standards.   
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Cell Survival (MTT) Assay 
 Cells were treated with either EF polar, EF apolar, EH polar, or EH apolar 
extracts at concentrations of 25, 50, or 125 µg/ml. The dissolution vehicle was dimethyl 
sulfoxide at a maximum final concentration of 0.3% in the treated well  (Sigma- Aldrich, 
St. Louis, MO) After 24 hours of incubation, 3-(4, 5-methyl-thiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide (MTT) (Sigma- Aldrich) was added at 500ug/ml/well for 3 hours.  In 
the mitochondria of cells, NADH-dependent cellular oxidoreductase enzymes, such as 
NADH dehydrogenase, reflect the number of viable cells.  These enzymes are capable of 
reducing the tetrazolium dye to its insoluble formazan, which is purple in color.  
Formazan products were solubilized with acidified 2-propanol (0.1N HCl). Assays were 
quantified by reading optical density at a wavelength of 590 nm using a Biotek 
PowerWave XS2 plate reader (Winooski, VT) [11].  Statistical analyses were used to 
determine the significance difference with p < 0.05.  Half maximal inhibitory 
concentrations were calculated and are shown in Table 2. 
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Results 
 
 
Figure 1: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human pancreatic cancer MiaPaca cells.  MiaPaca cells were dosing with 25, 
50, and 125 µg/mL of drug.  The control was dosed using dimethylsulfoxide 
(DMSO).  MTT assay was used to determine the percent of cell viability after 
dosing.  Significant difference between the control and each concentration was 
determined with p values < 0.05.   
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Figure 2: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human pancreatic cancer Panc28 cells.  Panc28 cells were dosed with 25, 50, 
and 125 µg/mL of drug.  The control was dosed using dimethylsulfoxide 
(DMSO).  MTT assay was used to determine the percent of cell viability after 
dosing.  Significant difference between the control and each concentration was 
determined with p values < 0.05.   
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Figure 3: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human colon cancer HCT-116 cells.  HCT-116 cells were dosed with 25, 50, 
and 125 µg/mL of drug.  The control was dosed using dimethylsulfoxide 
(DMSO).  MTT assay was used to determine the percent of cell viability after 
dosing.  Significant difference between the control and each concentration was 
determined with p values < 0.05.   
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Figure 4: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human colon cancer Caco-2 cells.  Caco-2 cells were dosed with 25, 50, and 125 
µg/mL of drug.  The control was dosed using dimethylsulfoxide (DMSO).  MTT 
assay was used to determine the percent of cell viability after dosing.  Significant 
difference between the control and each concentration was determined with p 
values < 0.05.   
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Figure 5: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human prostate cancer PC3 cells.  PC3 cells were dosed with 25, 50, and 125 
µg/mL of drug.  The control was dosed using dimethylsulfoxide (DMSO).  MTT 
assay was used to determine the percent of cell viability after dosing.  Significant 
difference between the control and each concentration was determined with p 
values < 0.05.   
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Figure 6: Effect of EH polar, EF polar, EH apolar, and EF apolar extracts on 
human prostate cancer LNCaP cells.  LNCaP cells were dosed with 25, 50, and 
125 µg/mL of drug.  The control was dosed using dimethylsulfoxide (DMSO).  
MTT assay was used to determine the percent of cell viability after dosing.  
Significant difference between the control and each concentration was determined 
with p values < 0.05.   
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Figure 7:  Effects of EH polar extract on human pancreatic, colon, and 
prostate cancer cells.  The effects of the EH polar extract on each cancer cell line 
is shown.  Cells were dosed with 25, 50, and 125 µg/mL of drug.  The control was 
dosed using dimethylsulfoxide (DMSO).  MTT assay was used to determine the 
percent of cell viability after dosing.  Significant difference between the control 
and each concentration was determined with p values < 0.05.   
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Figure 8:  Effects of EF polar extract on human pancreatic, colon, and 
prostate cancer cells.  The effects of the EF polar extract on each cancer cell line 
are shown.  Cells were dosed with 25, 50, and 125 µg/mL of drug.  The control 
was dosed using dimethylsulfoxide (DMSO).  MTT assay was used to determine 
the percent of cell viability after dosing.  Significant difference between the 
control and each concentration was determined with p values < 0.05.   
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Figure 9:  Effects of EH apolar extract on human pancreatic, colon, and 
prostate cancer cells.  The effects of the EH apolar extract on each cancer cell 
line are shown.  Cells were dosed with 25, 50, and 125 µg/mL of drug.  The 
control was dosed using dimethylsulfoxide (DMSO).  MTT assay was used to 
determine the percent of cell viability after dosing.  Significant difference 
between the control and each concentration was determined with p values < 0.05.   
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Figure 10:  Effects of EF apolar extract on human pancreatic, colon, and 
prostate cancer cells.  The effects of the EF apolar extract on each cancer cell 
line are shown.  Cells were dosed with 25, 50, and 125 µg/mL of drug.  The 
control was dosed using dimethylsulfoxide (DMSO).  MTT assay was used to 
determine the percent of cell viability after dosing.  Significant difference 
between the control and each concentration was determined with p values < 0.05.   
 
Cell line Mia Paca Panc 28 HCT116 Caco2 PC3 LNCaP 
 Extract       
EH Polar 33 70 37 63 31 16 
EF Polar 51 28 43 77 75 84 
EH apolar 88 21 42 94 61 67 
EF apolar >125 >125 >125 >125 79 106 
 
Table 2: Half maximal inhibitory concentrations (µg/mL) of each extract on 
pancreatic (MiaPaca, Panc28), colon (HCT-116, Caco2), and prostate (PC3, 
LNCaP). 
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Discussion 
 In this experiment, apolar and polar extracts from Gnaphalium gracile were tested 
for cytotoxic activity on colon, pancreatic, and prostate cancer of varying differentiation 
status.  The evidence supports the hypothesis that these extracts from the leaves and 
flowers had significant cytotoxic effect on the cells lines based on differentiation status in 
colon and pancreatic cancer, but not in prostate cancer.  Evidence suggests that cytotoxic 
activities are independent of tumorigenic potential of the cell lines characterized by the 
expression of Aldehyde dehydrogenase (ALDH) and other genetic markers [12].   
 A useful piece of information gathered from the data is the half maximal 
inhibitory concentration (IC50).  According to the FDA, the calculated IC50 value is the 
concentration of a drug in which 50% inhibition occurs in vitro [19].  This value is 
particularly useful because it quantifies the relative effectiveness of the drugs.  For 
example, for EH polar the IC50 value for MiaPaca is 33 µg/mL while it is 70 µg/mL for 
Panc28 (Table 2).  This is evidence that EH polar has more cytotoxic properties towards 
MiaPaca which is poorly differentiated as compared to Panc 28, but remains uncertain 
due to the mixture of compounds within this extract. 
 Overall, EH polar was the most effective at diminishing cancer cell viability.  It 
was effective against 4 of the 6 cell lines tested (Figure 7), while its closest competitor 
was EF polar (Figure 8) and EH apolar (Figure 9), which were only effective against the 
well differentiated pancreatic cancer cell line, Panc28.   
 IC50 values of PC3 and LNCaP prostate cancer of EH polar were 16 and 31 
µg/mL, respectively (Table 2). These cells lines are characterized largely due to their 
differentiation status.  PC3 is poorly differentiated, which makes it highly metastatic, 
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relative to LNCaP [20].  Among the mutagenic factors within these cell lines, both 
contain an overexpression of the oncogene k-ras [21].  This oncogene is responsible for 
regulating parts of cell division that are vital to growth and development, as well as 
specialization [22].  When mutated, as in the case of PC3 and LNCaP, this oncogene can 
lead to the development of a tumor in the prostate.  However, it appears that the activity 
of EH polar is independent of tumorigenic potential.  A useful measure of tumorigenic 
potential is the levels of aldehyde dehydrogenase (ALDH).  ALDH has been shown as a 
marker of tumorigenic potential, especially in PC3 and LNCaP.  Both cell lines contain 
low levels of ALDH [12].  In this way, the extract is effective against the prostate cancer 
cells lines, independent of tumorigenic potential because they contain similar levels of 
ALDH, and EH polar shows no preferential effect towards PC3 or LNCaP, with respect 
to ALDH levels.  Additionally, the effects of EH polar on these prostate cancer cells lines 
is also independent of the tumor suppressor gene p53, the androgen receptor (AR), and 
the prostate specific antigen (PSA) because LNCaP expresses these genes while PC3 
does not express these genes and proliferation is not dependent on androgen [23]. 
 According to Figure 7, there were also differential effects of EH polar on human 
colon cancer cell lines, HCT 116 and Caco 2.  These cell lines differ in their expression 
of several oncogenes, including APC, TP53, and SMAD4.  Caco 2 has been shown to 
have mutations in these oncogenes, but not in k-ras [24].  LNCaP does not express 
oncogenes in APC, TP53, or SMAD4.  This preferential effect of the extracts towards 
HCT-116 may be due in part to the lack of expression of these oncogenes.  As mentioned 
previously, both prostate cell lines expressed oncogenes and there was no preferential 
effect towards them.  Similarly, the extracts were more effective against the colon cancer 
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cell line that did not express these oncogenes.  This is further evidence to suggest that the 
extracts had cytotoxic effects due to differentiation status in colon cancer, but not 
tumorigenic potential. 
 In addition to EH polar, EF polar and EH apolar possessed cytotoxic effects 
against the better differentiated pancreatic cell line, Panc28, while there was no 
significant effect against the poorly differentiated pancreatic cell line, MiaPaca (Figure 8 
and 9).  MiaPaca may be resistant to treatment partially due to the overexpression of 
several oncogenes including serine/threonine kinase-15 (STK15), colony stimulating 
factor subclass I (CSF-I), and plasminogen activator [25].  EF polar and EH apolar have 
been shown to contain a high concentraton of 5,7-dihydroxy-3,8-dimethoxyflavone 
(gnaphalin A) [26].  This compound has tracheal smooth muscle relaxant properties [28] 
 
 
Chemical Structure of Gnaphalin A 
Source: Chemical Book 
 
 In a previous study, flavonoids such as quercetin and 3-methoxy-quercetin were 
identified in polar extracts from the leaves of Gnaphalium gracile [26].  These molecules 
may be responsible for the cytotoxic effects of EH polar.  Traditionally sold as a dietary 
supplement, quercetin has been associated with reduced risk of cancer [27]. 
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Chemical Structure of Quercetin 
Source: Chemical Book 
 
 The least effective extract was the apolar extract from flowers (EF apolar) 
(Figure 10).  This extract has previously been shown to contain high concentrations of 
substanes such as aromatic monoterpenes, fatty acids, and low concentration of gnaphalin 
A [26].  This may be the reason for the low cytotoxic effects of this extract on the cancer 
cells lines, relative to the other extracts.  
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Conclusion 
 These extracts from Gnaphalium gracile have shown cytotoxic effects on cancer 
cell lines from the pancreas (MiaPaca, Panc28), colon (HCT-116, Caco2), and prostate 
(PC3, LNCaP), which may be due to the difference in differentiation status, but definitely 
not of tumorigenic potential.  The polar and apolar have different activities based on 
characteristic molecules found within them in both leaves and flowers.  The cytotoxic 
effects of the extracts, particularly EH polar, show selective cytotoxic effects amongst 
tissue type, thus suggesting a preference for differentiation status.   
 Since these extracts contain numerous molecules, further research is needed to 
isolate the bioactive compounds within these extracts.  In order to develop an anticancer 
drug, these molecules must be identified and the mechanism of action must be 
characterized for the drug to be approved as an antitumor agent.  With this research, it is 
possible that the detrimental treatment options such as surgery, chemotherapy, and 
radiation may become less frequent as a treatment option for patients with pancreatic, 
colon, or prostate cancer.   
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